Olodaterol

beta2-Adrenergic Agonist — RESPIRATORY SYSTEM

Key facts

Olodaterol is an onp drug in the beta2-Adrenergic Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2014. Its mechanism of action is classified as Adrenergic beta2-Agonists. DrugCentral lists 3 molecular targets, including ADRB2, ADRB1 and ADRB3. Recorded indications include Chronic obstructive lung disease.

• Approval status: onp (first approved 2014 by the FDA).
• Drug class: beta2-Adrenergic Agonist.
• Mechanism of action: Adrenergic beta2-Agonists.
• Molecular targets: ADRB2, ADRB1 and ADRB3 (3 listed in DrugCentral).
• Indications: Chronic obstructive lung disease.
• ATC code: R03AC19 (Selective beta-2-adrenoreceptor agonists).
• Molecular formula: C21H26N2O5; molecular weight 386.45 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Chronic obstructive lung disease

Mechanism & targets

• Mechanism of action (MoA): Adrenergic beta2-Agonists
• Established pharmacologic class: beta2-Adrenergic Agonist

Molecular targets (3)

Target	Gene	Action	Activity
Beta-2 adrenergic receptor	ADRB2	antagonist	Ki 9.14
Beta-1 adrenergic receptor	ADRB1	unknown	Ki 7.33
Beta-3 adrenergic receptor	ADRB3	unknown	Ki 5.26

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2014-07-31	FDA	—	BOEHRINGER INGELHEIM

ATC classification

ATC code	Therapeutic hierarchy
R03AC19	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Selective beta-2-adrenoreceptor agonists
R03AL06	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Wheezing	67.3
Dyspnoea	53.0
Sleep disorder due to a general medical condition	50.6
Asthma	48.0
Therapeutic product effect incomplete	41.0
Asthma-chronic obstructive pulmonary disease overlap syndrome	38.1
Chronic obstructive pulmonary disease	37.4
Total lung capacity increased	34.9
Loss of personal independence in daily activities	33.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Olodaterol is on its molecule page.

• Molecular formula: C₂₁H₂₆N₂O₅
• Molecular weight: 386.45 g/mol
• CAS number: 868049-49-4
• InChIKey: COUYJEVMBVSIHV-SFHVURJKSA-N
• PubChem CID: 11504295

COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Olodaterol used for?

DrugCentral lists the following indications for Olodaterol: Chronic obstructive lung disease.

How does Olodaterol work?

Olodaterol is classified as Adrenergic beta2-Agonists; its molecular targets in DrugCentral include ADRB2 (antagonist), ADRB1 and ADRB3.

When was Olodaterol first approved?

Olodaterol was first approved by the FDA in 2014.

What drug class does Olodaterol belong to?

Olodaterol is in the beta2-Adrenergic Agonist class.

What is the chemical formula of Olodaterol?

Olodaterol has the molecular formula C21H26N2O5 and a molecular weight of 386.45 g/mol.

Sources

• DrugCentral drug card 4814 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2105743 — compound record and bioactivity
• PubChem CID 11504295 — chemical identifiers
• DrugBank DB09080 — drug record
• FDA UNII VD2YSN1AFD — substance identity
• DailyMed: FDA labels for Olodaterol — current prescribing information (label search)
• UniProt P07550 (ADRB2) — target protein
• UniProt P08588 (ADRB1) — target protein
• UniProt P13945 (ADRB3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.